Abbreviations: AUC, area under the curve; D, D-score; DOR, diagnostic odds ratio; EH, endometrial hyperplasia; EIN, endometrial intraepithelial neoplasia; LR+, positive likelihood ratio; LR−, negative likelihood ratio; PTEN, tumor suppressor protein phosphatase and tensin homolog; SROC, summary receiver operating characteristic; WHO, World Health Organization. 
| INTRODUC TI ON
Endometrial hyperplasia (EH) is an irregular proliferation of endometrial glands with increased gland to stroma ratio when compared with the normal proliferative endometrium.
1 It may be a benign condition caused by an unopposed action of estrogens or a precancerous process. 2, 3 It is necessary to distinguish between these two conditions. In fact, premalignant EH requires total hysterectomy, or a conservative progestin-based therapy with close follow up in selected women. On the other hand, benign EH may be managed with observation alone, or with progestins when symptomatic. 4, 5 Two different systems have been proposed to classify EH: the World Health Organization (WHO) system and the endometrial intraepithelial neoplasia (EIN) system.
2,3
The WHO system distinguishes "EH without atypia" (benign)
from "atypical EH" (premalignant) based on the presence of cytologic atypia.
1,2
The EIN system distinguishes "benign EH" from "endometrial intraepithelial neoplasia" based on a combination of histologic criteria.
The EIN system may also be applied objectively through a computerized morphometric analysis; such analysis allows calculation of the "morphometric D-score," which subdivides EH into "high/intermediate risk" (D-score [D] ≤ 1) or "low risk" (D > 1) of progression to cancer.
2,3
In the revised 2014 WHO classification, the terms "atypical EH"
and EIN are reported as synonyms, although EIN refers to "endometrioid intraepithelial neoplasia."
1
The histologic evaluation is considered the gold standard in the differential diagnosis between benign and premalignant EH. The WHO system is recommended by the Royal College of Obstetricians and Gynaecologists, whereas the EIN system is recommended by the American College of Obstetricians and Gynecologists. 4, 5 Nonetheless, histologic classifications may be affected by several problems, such as low reproducibility, tissue inadequacy, artefact changes, or ambiguous features. 3, 6 To improve the reliability of the differential diagnosis, several diagnostic markers have been proposed. Great emphasis has been given to the loss of expression of the tumor suppressor protein phosphatase and tensin homolog (PTEN), 2, 7 because the mutation of PTEN is the most common molecular alteration found in endometrial carcinogenesis 8, 9 and occurs in an early phase. 7, 9 In the 10 In spite of this, the several studies in the literature showed a highly variable degree of association between loss of PTEN expression and premalignant EH, missing an analysis of diagnostic accuracy.
The actual usefulness of immunohistochemistry for PTEN has never been defined.
The aim of this study was to determine the diagnostic accuracy of immunohistochemical assessment of PTEN in differential diagnosis between benign and premalignant EH, by extracting data from the available literature.
| 277
All peer-reviewed retrospective or prospective studies assessing the immunohistochemical expression of PTEN on histological specimens of premalignant EH (atypical EH/endometrial intraepithelial neoplasia) or benign EH (EH without atypia/benign EH) were included in the systematic review.
Exclusion criteria were:
1. data on PTEN expression not extractable;
2. no distinction between premalignant and benign EH;
3. case reports and reviews;
4. patient data overlapping with a study already included.
Only the studies assessing both premalignant and benign EH were included in the meta-analysis.
According to the revised Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), 13 four domains related to risk of bias were assessed in each study: (1) Review authors' judgments were categorized as "low risk," "high risk," or "unclear risk" of bias.
Data from each eligible study were extracted without modification of the original data. Two-by-two contingency tables were prepared for each study, reporting two dichotomous qualitative variables:
1. PTEN expression ("loss" or "presence"), which was the index test; 2. histological diagnosis ("precancerous" or "benign"), which was the reference standard.
Precancerous cases with PTEN loss were considered as true positives, benign cases with PTEN presence were considered as true negatives, precancerous cases with PTEN presence were considered as false negatives, and benign cases with PTEN loss were considered as false positives.
Data regarding the index test were extracted by using the following criteria:
1. for the studies dichotomizing PTEN expression (positive vs negative) independently from distribution and intensity of expression, "negative" was considered as "PTEN loss";
2. for the studies using a semi-quantitative scale to grade the intensity of PTEN expression, independently from the distribution, the lowest grade (negative expression) was considered as "PTEN loss";
3. for the studies assessing the percentage of PTEN-positive glands, independently from the intensity of staining, the lowest percentage (negative expression) was considered as "PTEN loss."
Data regarding the reference standard were extracted by using the following criteria:
1. for the studies using the WHO classification, atypical EH (simple or complex) was considered as "precancer," while EH without atypia (simple or complex) was considered as "benign";
2. for the studies using the EIN classification, endometrial intraepithelial neoplasia or high/intermediate-risk EH (D ≤ 1) were considered as "precancer," while benign EH or low-risk EH (D < 1)
were considered as "benign";
3. hyperproliferative conditions caused by unopposed action of estrogens (eg "disordered proliferative endometrium," "persistent proliferative endometrium") were included in the "benign" group, as proposed in the literature, 14 because they constitute a pathologic continuum with non-atypical EH.
6
When discrepancies between values reported in the text and the tables were found, values from tables were used for the analysis. Data were also subdivided into two subgroups based on the classification system adopted (WHO vs EIN).
Sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR−), and diagnostic odds ratio (DOR) were calculated for each study and as pooled estimate using the random effect model of DerSimonian and Laird and reported graphically on forest plots, with 95% CI. Statistical heterogeneity among studies was assessed using the Higgins I 2 statistic; heterogeneity was considered insignificant for I 2 < 25%, low for I 2 < 50%, moderate for I 2 < 75%, and high for I 2 ≥ 75%.
Area under the curve (AUC) was calculated on summary receiver operating characteristic (SROC) curves. The diagnostic usefulness was considered absent for AUC ≤ 0.5, low for 0.5 < AUC ≤ 0.75, moderate for 0.75 < AUC ≤ 0.9, high for 0.9 < AUC < 0.97, and very high for AUC ≥ 0.97.
As additional analysis, we performed a subgroups analysis, assessing sensitivity, specificity, LR+, LR−, DOR, and AUC separately for the two subgroups.
The data analysis was performed using Review ManageR 5.3 
| RE SULTS
We identified 635 articles through database searching and 13 through additional sources. After duplicate removal, 189 articles remained and 101 were screened. Forty-four articles were considered relevant and so were assessed for eligibility; 17 of them were excluded by applying our exclusion criteria. Finally, 27 studies were included in the systematic review, 18 of which were suitable for the meta-analysis. Details about the whole process of study selection are shown in Figure 1 .
Twenty-seven observational studies were included in the sys- Details about characteristics of the included studies and methods for immunohistochemistry are shown in Tables 1 and 2 , respectively.
Results of the risk of bias assessment are shown in Figure 2 . In particular, for the "patient selection" domain, three studies were classified as being at unclear risk of bias, because they followed a case-control design; nine studies were considered at high risk of bias because they selected only premalignant EH. All the remaining studies were considered at low risk.
For the "index test" domain, five studies were considered at unclear risk of bias, because they only used a qualitative scale to grade PTEN expression, regardless of the percentage of stained cells. The other studies were considered at low risk.
For the "reference standard" domain, 17 studies were classified as being at low risk of bias, because they specified that histological slides were reviewed to confirm the diagnosis of benign or premalignant. The other 10 studies were considered at unclear risk.
For the "flow and timing" domain, all the included studies were classified as being at low risk of bias, since both the index and the reference standard were performed on the same specimen and for all patients.
Eighteen studies assessing 1362 EH were included in the meta- Among the included studies, the heterogeneity was high in sensitivity (I 2 = 80%) and specificity (I 2 = 92.5%), low in LR+ (I 2 = 43.2%), moderate in LR− (I 2 = 56.9%), and insignificant in DOR (I 2 = 23.5%).
The SROC curves analysis demonstrated low overall accuracy with an AUC of 0.657.
Results are reported graphically in forest plots and SROC curves in Figure 3 .
In the subgroup analysis, 12 studies assessing 934 EH by using the WHO system were included in first subgroup; 295 (31.6%) of total EH were premalignant and 639 (68.4%) were benign.
Pooled sensitivity and specificity were 59% (95% CI 53%-65%) and 65% (95% CI 62%-69%), respectively, with pooled LR+ and The SROC curves analysis demonstrated low overall accuracy with an AUC of 0.694.
Six studies assessing 428 EH by using the EIN system were included in the second subgroup; 178 (41.6%) of total EH were premalignant and 250 (58.4%) were benign.
Pooled sensitivity and specificity were 47% (95% CI 39%-54%) and 69% (95% CI 63%-74%), respectively, with pooled LR+ and LR− 
| D ISCUSS I ON
Although a loss of PTEN function is involved in endometrial carcinogenesis, our study showed that immunohistochemical evaluation of PTEN expression has a low diagnostic usefulness in the differential diagnosis between benign and premalignant EH.
The PTEN gene is located at chromosome 10q23 and encodes a phosphatase that acts as a tumor suppressor. It has a lipid phosphatase activity, which induces cell cycle arrest, upregulates
AKT-dependent pro-apoptotic mechanisms and downregulates
Bcl-2-dependent anti-apoptotic mechanisms, acting in opposition to phosphatidylinositol 3-kinase (PI3K). Moreover, PTEN has also a protein phosphatase activity, which is involved in the inhibition of focal adhesion formation, cell spread, and growth-factor-stimulated mitogen-activated protein kinase (MAPK) signaling.
41
In the four categories of endometrial cancer identified by the Cancer Genome Atlas Research Network (ultramutated, hypermutated, copy number low, copy number high), PTEN mutations were found in 94%, 88%, 77%, and 15% of cases, respectively. Such a test would determine which women should be treated to prevent cancer, so a high sensitivity appears crucial in order not to miss patients at risk. For this reason, a sensitivity of 59% appears to be not enough. On the other hand, as hysterectomy is the reference standard intervention for premalignant EH, a high specificity is also needed to avoid severe overtreatment. Hence, the specificity observed (66%) is too low. Given these findings, PTEN assessment appears inadequate as a stand-alone diagnostic test.
However, a suboptimal sensitivity might be expected, because not all endometrioid adenocarcinomas or their precursor lesions have underlying mutations of the PTEN gene. 8, 9 Concerning the low specificity, a possible cause may be that a loss of PTEN expression does not necessarily indicate a monoclonal lesion. In fact, Yilmaz et al observed PTEN loss using immunohistochemistry in 3/36 (8.3%) polyclonal endometrial specimens.
42
Furthermore, a loss of PTEN expression may be observed in morphologically normal clones of endometrial glands, which tend to spontaneously regress. Mutter et al showed that only a small proportion (6.7%) of these latent precancers actually progress to overt lesions.
43
In the WHO subgroup, higher sensibility and DOR, and lower specificity, LR+, and LR−, were found when compared with the EIN subgroup. This resulted in a greater AUC for the WHO subgroup.
The heterogeneity was higher in the WHO subgroup for all analyses, possibly because of the better reproducibility of the EIN system.
2,3
In a comparison study, the prognostic ability of the two classifications appeared to be superimposable.
14 A possible cause of both the higher diagnostic accuracy and the heterogeneity for the WHO subgroup may be found in the "smallstudy effect." Nonetheless, a meta-epidemiological study published in 2014 showed that such an effect was not significant in meta-analyses of diagnostic test accuracy.
44
To the best of our knowledge, this study is the first meta-anal- Major limitations to our results might be the intra-and inter-observer variability for both index test and reference standard. Such Concerns about the index text regard the lack of standardized and objective criteria for interpreting PTEN immunostaining.
However, it was shown that a subjective categorization of PTEN immunostaining as "normal," "heterogeneous," or "loss," was highly reproducible.
45
Regarding the reference standard, well-described concerns relate to the variability in the histologic criteria. In particular, the diagnosis of cytologic atypia has shown poor reproducibility. 2, 46 Furthermore, the characteristics of atypia specific for endometrial epithelium are not included in the WHO classification system, and metaplastic and regenerative changes may mimic true atypia. 1, 6, 46 Other concerns refer to the fact that premalignant hyperplasia is a focal change, [1] [2] [3] 47 and the amount of tissue/cells harboring the atypical features may be scant, particularly in aspiration biopsies or curettage samples. 2, 6 In addition, the degree of atypia is often variable, further complicating the determination of diagnostic atypia. 46 As discussed, the 2014 In our opinion, further studies in this field should improve the reliability of both the index test and the reference standard.
The reliability of the index test might be improved by standardizing criteria for interpreting PTEN immunostaining, in terms of intensity of staining and percentage of stained cells. The antibody to be used should also be standardized. Among the available anti-PTEN antibodies, it is unclear which one should be used. In fact, the clone 6H21 was used in the study showing the highest DOR, 38 as well as in the one showing the lowest DOR. 29 A study published in 2011 suggested the clone 138G6 to be the most reliable. 48 In our systematic review, the only study using such a clone was not included in the meta-analysis because of the lack of a control group of benign EH.
34
On the other hand, the reliability of the reference standard might be partially improved through consensus among several pathologists in the evaluation of histologic slides. A combination of several markers more specific than PTEN (such as Bcl- 2 49 ) might considerably reduce the variability of the reference standard.
However, given the limitations inherent to PTEN and discussed above, it is probable that the diagnostic usefulness of PTEN alone F I G U R E 5 Forest plots of individual studies and pooled sensitivity (A), specificity (B), positive likelihood ratio (C), negative likelihood ratio (D), and diagnostic odds ratio (E) of PTEN immunohistochemical assessment in differential diagnosis between benign and premalignant endometrial hyperplasia, with summary receiver operating characteristic curves (F), for the endometrial intraepithelial neoplasia subgroup [Color figure can be viewed at wileyonlinelibrary.com] might be fair at best, even with optimized criteria. Further studies appear necessary to clarify the prognostic value of PTEN immunohistochemistry in EH, with specific regard to the progression to cancer.
| CON CLUS ION
Although a loss of PTEN expression was associated with endometrial precancer, immunohistochemistry for PTEN showed a low diagnostic usefulness in the differential diagnosis between benign and premalignant EH, independently from the histologic classification used (WHO or EIN). In the absence of further evidence, the recommendation about the use of PTEN for this purpose should be reconsidered.
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